Contrast Media Injectors Market Size to Reach $1.4 Billion by 2025: Grand View Research, Inc.
SAN FRANCISCO, December 12, 2017 /PRNewswire/ --
The global contrast media injectors market is expected to reach USD 1.4 billion by 2025, growing at a CAGR of 5.8%, according to a new report by Grand View Research, Inc. Rising demand for minimally invasive surgical procedures is a major factor expected to boost the market during the forecast period. These devices assist surgeons in accurate insertion of contrast agents with reduced human errors, thus increasing the accuracy and efficiency of surgical procedures. They play a crucial role in Intraoperative Computed Tomography (iCT), Intraoperative Magnetic Resonance Imaging (iMRI), and interventional cardiology. Availability of advanced injector systems for diagnosis and intraoperative imaging has boosted adoption of these systems. For instance, Medrad Stellant CT injection system integrated with Certegra Workstation provides high efficiency and accuracy in CT imaging.
Technological advancements, such as automated contrast media injectors and double-head injectors, are also among major factors supporting the growth of the market. Automated contrast media injectors provide improved patient safety, accuracy, and enhance image quality. Also, double-head injectors allow a large and rapid initial bolus of contrast, which is required in several imaging procedures. For instance, in cardiac CT, a fast injection is required for imaging of both sides of the ventricular septum to identify septal thickness, shunts, and enlarged ventricles. Delivery of contrast media is more efficient and controlled with a dual-head injector.
Browse full research report with TOC on"Contrast Media Injectors Market By Product (Injector Systems, Consumables), By Type (Single Head, Dual-Head, Syringeless Injectors), By Application, By End-use, And Segment Forecasts, 2014 - 2025" at:https://www.grandviewresearch.com/industry-analysis/contrast-media-injectors
Further Key Findings From the Report Suggest:
CT injector systems segment was the largest revenue-generating segment of the market in 2016 owing to availability of technologically advanced products and their widespread application for disease diagnosis and image-guided surgeries
The single head injectors segment accounted for the largest revenue share in 2016 and is expected to maintain its dominance throughout the study period
In the application segment, interventional cardiology is projected grow at the highest rate during the forecast period because of rising prevalence of cardiac diseases, such as coronary artery disease, heart valve disease, and peripheral vascular disease
In 2016, hospitals dominated the contrast media injectors market in terms of revenue because of an increase in the number of hospital admissions of patients suffering from cancer, neurological disorders, and cardiovascular diseases
The North America contrast media injectors market held the largest revenue share in 2016 and is projected to maintain its dominance during the forecast period owing to well-established healthcare infrastructure
Some of the major players are Bayer HealthCare LLC; Guerbet Group; Bracco Group; Medtron AG; GE Healthcare; Nemoto Kyorindo Co., Ltd.; Ulrich GmbH & Co. KG; VIVID IMAGING; Sino Medical-Device Technology Co., Ltd.; and APOLLO RT Co. Ltd.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact: Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Ecolab will host a live webcast of its annual meeting of stockholders. As indicated in our proxy statement, the 2024 Annual Meeting of Stockholders will be a virtual-only meeting.
Details for the public webcast are as follows:
TIME:...
Summit Therapeutics Inc. ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens....
Hapbee Technologies, Inc. ("Hapbee" or the "Company"), the digital wellness technology company is pleased to confirm that it has completed a non-brokered private placement of units of the Company ("Units") for aggregate gross proceeds to the...
Collaboration on TSMC's COUPE silicon photonics platform dramatically speeds chip-to-chip and machine-to-machine communication for cloud, datacenters, HPC, and AI chips
/ Key Highlights
Ansys and TSMC deliver a high-fidelity multiphysics solution to...
The Board of Directors of The Cigna Group today declared a cash dividend of $1.40 per share of its common stock, payable on June 20, 2024 to shareholders of record as of the close of business on June 4, 2024....
Deverra Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA)...